Keyphrases
Acquired Resistance
100%
Altered Pathway
33%
Anti-PD-1 Immunotherapy
100%
Anti-programmed Death 1
100%
CD4+
33%
CD8+ Tumor-infiltrating Lymphocytes
33%
Clinical Trials
33%
Functional Analysis
33%
IFN Signaling
100%
Immune Escape
66%
Immune Resistance
33%
Janus Kinase 1 (JAK1)
66%
Lymphocyte Activation gene-3 (LAG-3)
33%
Melanoma
100%
MHC Class I Antigen Presentation
100%
Objective Response
33%
Resistance to Immunotherapy
33%
Response to Immunotherapy
33%
T Cells
66%
Tumor Cells
33%
Tumor Killing
33%
Tumor Progression
33%
β2-microglobulin (β2-MG)
66%
Medicine and Dentistry
Antigen Presentation
100%
Beta 2 Microglobulin
66%
CD8 Antigen
33%
Clinical Trial
33%
Immunity
33%
Immunotherapy
100%
Janus Kinase 1
66%
Lymphocyte Activation
33%
Neoplasm
33%
Nodular Melanoma
100%
T Cell
66%
Tumor Cell
33%
Tumor Infiltrating Lymphocyte
33%
Tumor Progression
33%
Immunology and Microbiology
Antigen Presentation
100%
Beta-2 Microglobulin
66%
CD4
33%
CD8
33%
Immune Escape
66%
Immunity
33%
Immunotherapy
100%
Lymphocyte Activation
33%
MHC Class I
100%
T Cell
66%
Tumor Cell
33%
Tumor-Infiltrating Lymphocytes
33%